摘要
目的:探讨血清同型半胱氨酸在糖尿病肾病中的检测价值。方法:选择2014年8月-2015年10月本院收治的2型糖尿病患者80例,将其根据血肌酐、尿白蛋白排泄率水平分为A、B、C、D组,A组为单纯糖尿病患者19例、B组为早期糖尿病肾病患者25例、C组为临床糖尿病肾病患者20例、D组为肾衰竭患者16例,另选同期进行健康体检者35例作为对照组进行分析,分别抽取其空腹静脉血3 m L,离心后采用循环酶法检测其血清同型半胱氨酸水平情况。结果:A、B、C、D组空腹血糖、胆固醇比较,差异均无统计学意义(P>0.05);A、B、C、D组空腹血糖、胆固醇、尿白蛋白排泄率与对照组比较,差异均有统计学意义(P<0.05);A、B、C、D组尿白蛋白排泄率、血清同型半胱氨酸水平呈递增趋势,组间比较差异均有统计学意义(P<0.05)。结论:血清同型半胱氨酸在糖尿病肾病中具有较高的检测价值,其水平高低可在一定程度上反映糖尿病肾病患者肾脏的损害程度,为糖尿病肾病的一个独立危险因素,可将其作为判断2型糖尿病发生发展的检测指标。
Objective： To explore the detection value of serum homocysteine in diabetic nephropathy. Method： Eighty patients with type 2 diabetes mellitus admitted in our hospital from August 2014 to October 2015 were selected, they were divided into group A （ 19 patients with pure diabetes ）, group B （ 25 patients with early diabetic nephropathy ）, group C （ 20 patients with clinical diabetic nephropathy ） and group D （ 16 patients with renal failure ）, 35 cases with physical examinations were selected as the control group over the same period, 3 mL of fasting venous bloods of patients were extracted respectively, and the serum level of homocysteine was detected by circle enzyme after centrifugationt.Result： The comparisons in fasting blood sugar and cholesterol of patients in group A, group B, group C and group D were not significantly different （ P〉0.05 ） .The comparisons in excretion rates of fasting blood glucose, cholesterol and urinary albumin of patients in group A, group B, group C and group D, compared with the control group, there Was statistical significance （ P〈0.05 ） .The excretion rates of urine albumin and levels of serum homocysteine of patients in group A, group B, group C and group D showed the tendency of progressive, and inter-group comparison differences were significant （P〈O.05） .Conclusions： Serum homocysteiney delivers great detection value in diabetic nephropath, and its level can reflect the renal damage of patients with diabetic nephropathy, serum homocysteiney as an independent risk factor for diabetic nephropathy, can serve as a detection indicator to judge the occurrence and development of type 2 diabetes.
出处
《中国医学创新》
CAS
2016年第22期138-141,共4页
Medical Innovation of China
